News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
TFOS is indicated for the treatment of pulmonary arterial hypertension
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The inspection was carried out from January 28 to February 1, 2025
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Subscribe To Our Newsletter & Stay Updated
